Screener
CONMED CNMD Contingent consideration fair value adjustments
Contingent consideration fair value adjustments at other companies
Other financials
Where this comes from
Reported directly by CONMED in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.
The source filing: CONMED’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000816956-26-000102
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Stock-based compensation | 10,732 | 18,766 |
| Deferred income taxes | 3,683 | (975) |
| Gain on sale of product offerings, net | (1,512) | — |
| Non-cash adjustments to fair value of contingent consideration liability | 610 | 2,163 |
| (Gain) loss on early extinguishment of debt, net | (4,597) | 363 |
| Increase (decrease) in cash flows from changes in assets and liabilities: | ||
| Accounts receivable | 7,255 | 11,147 |
| Inventories | (13,706) | (13,026) |
Item 1. Financial Statements (unaudited)
FAQ
- What is CONMED's contingent consideration fair value adjustments?
- CONMED (CNMD) reported contingent consideration fair value adjustments of -$113K in Q2 2026.
- How has CONMED's contingent consideration fair value adjustments changed year-over-year?
- CONMED's contingent consideration fair value adjustments increased by 93.7% year-over-year, from -$1.8M to -$113K.
- What is the long-term trend for CONMED's contingent consideration fair value adjustments?
- Over 2 years (2023 to 2025), CONMED's contingent consideration fair value adjustments has grown at a 207.9% compound annual growth rate (CAGR), from -$2.42M to $22.95M.
Ask your AI about CONMED's contingent consideration fair value adjustments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude